CVA Family Office LLC Has $451,000 Stake in Bristol-Myers Squibb (NYSE:BMY)

CVA Family Office LLC raised its holdings in Bristol-Myers Squibb (NYSE:BMY) by 9.1% in the third quarter, Holdings Channel reports. The fund owned 8,724 shares of the biopharmaceutical company’s stock after acquiring an additional 731 shares during the period. CVA Family Office LLC’s holdings in Bristol-Myers Squibb were worth $451,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of BMY. Voisard Asset Management Group Inc. acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth about $73,000. Able Wealth Management LLC acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth about $90,000. GLOBALT Investments LLC GA acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth about $3,570,000. Garde Capital Inc. boosted its position in shares of Bristol-Myers Squibb by 23.9% during the fourth quarter. Garde Capital Inc. now owns 2,527 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 487 shares during the period. Finally, Raleigh Capital Management Inc. boosted its position in shares of Bristol-Myers Squibb by 186.1% during the fourth quarter. Raleigh Capital Management Inc. now owns 3,966 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 2,580 shares during the period. 76.41% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts recently commented on the company. TD Cowen increased their price target on Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a “hold” rating in a research report on Monday, October 7th. Deutsche Bank Aktiengesellschaft reduced their price target on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a research report on Tuesday, July 23rd. StockNews.com raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 29th. UBS Group increased their price target on Bristol-Myers Squibb from $50.00 to $54.00 and gave the company a “neutral” rating in a research report on Wednesday. Finally, BMO Capital Markets reissued a “market perform” rating and set a $48.00 price target on shares of Bristol-Myers Squibb in a research report on Monday, September 23rd. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $53.00.

Bristol-Myers Squibb Stock Performance

Shares of NYSE BMY traded down $0.20 during trading hours on Friday, reaching $52.20. 6,041,711 shares of the stock were exchanged, compared to its average volume of 14,922,521. The firm has a market capitalization of $105.81 billion, a price-to-earnings ratio of -16.84, a P/E/G ratio of 13.75 and a beta of 0.46. The company has a debt-to-equity ratio of 2.86, a quick ratio of 1.02 and a current ratio of 1.16. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $57.65. The stock’s fifty day simple moving average is $49.75 and its 200 day simple moving average is $46.39.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $1.64 by $0.43. The company had revenue of $12.20 billion for the quarter, compared to analyst estimates of $11.54 billion. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The firm’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same quarter last year, the company earned $1.75 earnings per share. Sell-side analysts predict that Bristol-Myers Squibb will post 0.77 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, November 1st. Investors of record on Friday, October 4th will be given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 4.60%. The ex-dividend date of this dividend is Friday, October 4th. Bristol-Myers Squibb’s dividend payout ratio is currently -77.42%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.